Efficacy and safety of disitamab vedotin (RC48) combined with toripalimab as adjuvant therapy after radical surgery for patients with HER2-overexpression upper tract urothelial cancer (UTUC): A single-arm, prospective, phase 2 clinical trial.
Shouyong Liu(Nanjing General Hospital of Nanjing Military Command), Le Qu(Nanjing General Hospital of Nanjing Military Command), Dian Fu(Nanjing University), Zhenyu Xu(Nanjing General Hospital of Nanjing Military Command), Haowei He(Nanjing General Hospital of Nanjing Military Command), Miao He(Guangdong General Hospital), Feng Xu(North Sichuan Medical University), Wenquan Zhou(Nanjing General Hospital of Nanjing Military Command), Song Xue(Zhujiang Hospital), Jingping Ge(Heilongjiang University)
Cited by 2
Related Papers
Exosome-Transmitted lncARSR Promotes Sunitinib Resistance in Renal Cancer by Acting as a Competing Endogenous RNA
|Cancer Cell|2016|1.2k
Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer
|Annals of Oncology|2014|603
Long noncoding RNA MRCCAT1 promotes metastasis of clear cell renal cell carcinoma via inhibiting NPR3 and activating p38-MAPK signaling
|Molecular Cancer|2017|257
Clinical and molecular effects on mature burn scars after treatment with a fractional CO<sub>2</sub> laser
|Lasers in Surgery and Medicine|2012|153